Patents/Inventors

Hans G. Klingemann

Culver City, CAUS18 patents

17 Patents

US125841382026
Quadricistronic System Comprising a Homing Receptor and Chimeric Antigen Receptor for Stable Genetic Modification of Cellular Immunotherapies
Immunitybio, Inc.
0 cites
US124983632025
Combined Invasion and Cytotoxicity Assay Using Chemokine Secreting Target Cells
Immunitybio, Inc.
0 cites
US124733472025
Elimination of Pd-l1-positive Malignancies by PD-L1 Chimeric Antigen Receptor-expressing NK Cells
Immunitybio, Inc.
0 cites
US124733482025
Elimination of Pd-l1-positive Malignancies by PD-L1 Chimeric Antigen Receptor-expressing NK Cells
Immunitybio, Inc.
0 cites
US124351222025
Fc-epsilon CAR
Immunitybio, Inc.
0 cites
US124031782025
Use of CD33CAR Modified High Affinity NK Cells (t-hank) to Reduce Myeloid-derived Suppressor Cells Suppressor Activity (or Reduce Negative Impact on NK Cell Activity)
Immunitybio, Inc.
0 cites
US123848522025
Genetically Modified NK-92 Cells Having a Safety Switch
Immunitybio, Inc.
0 cites
US123783002025
Elimination of Cd19-positive Lymphoid Malignancies by Cd19-car Expressing NK Cells
Immunitybio, Inc.
0 cites
US123658742025
Chimeric Antigen Receptor-modified NK-92 Cells Targeting EGFR Super-family Receptors
Immunitybio, Inc.
0 cites
US121802832024
Anti-b7-h4 Chimeric Antigen Receptor-modified NK-92 Cells
Culver City, Inc.
0 cites
US121092382024
Chimeric Antigen Receptor-modified NK-92 Cells
Immunitybio, Inc.
0 cites
US120644502024
Tumoricidal and Antimicrobial Compositions and Methods
Immunitybio, Inc.
0 cites
US119925042024
Cell-mediated Transient Delivery of Immune-enhancing Molecules Into the Tumor Microenvironment
Immunitybio, Inc.
0 cites
US119750272024
Tumoricidal and Antimicrobial Compositions and Methods
Immunitybio, Inc.
0 cites
US118132922023
Use of CD33CAR Modified High Affinity NK Cells (t-hank) to Reduce Myeloid-derived Suppressor Cells Suppressor Activity (or Reduce Negative Impact on NK Cell Activity)
Immunity Bio, Inc.
0 cites
US116434522023
Fc-epsilon Car
Immunitybio, Inc.
0 cites
US115477272023
Chimeric Antigen Receptor-modified NK-92 Cells
Immunitybio, Inc.
0 cites